The following is an interview with Dr Matthew Zibelman, assistant professor in the Department of Hematology/Oncology at Fox Chase Cancer Center in Philadelphia, USA, at the OncLive® State of the Science SummitTM on Advanced Renal Cell Carcinoma and Bladder Cancer. Dr Zibelman discussed the promise of immunotherapy combinations for patients with kidney cancer.

Immunotherapy combinations are showing significant potential for the treatment of patients with kidney cancer, and may be better tolerated, suggested Dr Zibelman.

Read the full interview on OncLive here